WO2001045692A9 - Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them - Google Patents
Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using themInfo
- Publication number
- WO2001045692A9 WO2001045692A9 PCT/US2000/035178 US0035178W WO0145692A9 WO 2001045692 A9 WO2001045692 A9 WO 2001045692A9 US 0035178 W US0035178 W US 0035178W WO 0145692 A9 WO0145692 A9 WO 0145692A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sertraline hydrochloride
- hydrochloride form
- sertraline
- solvent
- suspension
- Prior art date
Links
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 title claims abstract description 456
- 229960003660 sertraline hydrochloride Drugs 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims abstract description 125
- 230000008569 process Effects 0.000 title claims abstract description 84
- 239000000203 mixture Substances 0.000 title claims description 61
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 113
- 229960002073 sertraline Drugs 0.000 claims description 112
- 239000000725 suspension Substances 0.000 claims description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 86
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 81
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 75
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- 239000002904 solvent Substances 0.000 claims description 64
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 62
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- 238000010438 heat treatment Methods 0.000 claims description 36
- 230000009466 transformation Effects 0.000 claims description 36
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 29
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- 238000010992 reflux Methods 0.000 claims description 28
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 27
- 239000012453 solvate Substances 0.000 claims description 24
- 238000004090 dissolution Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 17
- 238000001556 precipitation Methods 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000012454 non-polar solvent Substances 0.000 claims description 7
- 208000019906 panic disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 50
- 239000002585 base Substances 0.000 description 45
- 239000013078 crystal Substances 0.000 description 32
- 238000001914 filtration Methods 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 30
- 239000000843 powder Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000007792 addition Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- -1 t-butyl- Chemical group 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002083 X-ray spectrum Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000000441 X-ray spectroscopy Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PEBKGVSIRFSIGW-UHFFFAOYSA-N (2-methylnaphthalen-1-yl)azanium;chloride Chemical compound Cl.C1=CC=CC2=C(N)C(C)=CC=C21 PEBKGVSIRFSIGW-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to novel polymorphic Forms XI, XH, XIII, XIV, XV
- hydrochloride produced by the method of the '518 patent has a crystalline form
- the present invention includes new polymorphic forms of sertraline
- hydrochloride Polymorphic forms of a compound can be distinguished in a laboratory
- hydrochloride forms that have been designated Forms NI, Nil, Ni ⁇ , IX and X.
- the present invention relates to novel forms of sertraline hydrochloride.
- present invention provides processes for preparing sertraline hydrochloride Forms XI,
- sertraline hydrochloride Forms XI-XNI methods of using sertraline hydrochloride Forms
- sertraline hydrochloride Forms XI-XNI to treat depression, obsessive-compulsive
- the present invention relates to sertraline hydrochloride Form XI which is
- the present invention also relates to a process for making sertraline hydrochloride
- Form XI comprising the steps of: (a) dissolving sertraline hydrochloride in benzyl
- the present invention also relates to sertraline hydrochloride Form XI where
- sertraline hydrochloride Form XI is sertraline hydrochloride Form XI benzyl alcohol
- the present intention also relates to sertraline hydrochloride Form XI benzyl
- the present invention also relates to a method of making sertraline hydrochloride
- Form X comprising the step of heating sertraline hydrochloride Form XI.
- the present invention also relates to sertraline hydrochloride Form XII which is
- the present invention also relates to a process for making sertraline hydrochloride
- Form XII comprising the steps of: (a) exposing sertraline hydrochloride to water vapor;
- the process for making sertraline hydrochloride Form XII comprises the steps
- the present invention also relates to sertraline
- hydrochloride Form XII hydrates including sertraline hydrochloride Form XII mono-
- the present invention also relates to sertraline hydrochloride Form XIV which is
- the present invention also relates to a process for making sertraline hydrochloride
- Form XIV comprising the steps of: (a) dissolving sertraline base in a solvent mixture of
- the present invention also relates to a process for making sertraline hydrochloride
- Form XIV comprising the steps of: (a) adding sertraline hydrochloride Form II to
- the present invention also relates to a process for making sertraline hydrochloride
- Form V comprising the steps of: (a) heating sertraline hydrochloride Form XIN; and (b)
- the present invention also relates to sertraline hydrochloride Form XQI which is
- the present invention also relates to a process for making sertraline hydrochloride
- Form XIII comprising the steps of: (a) heating sertraline hydrochloride Form XIN; and
- the present invention also relates to a process for making sertraline hydrochloride
- Form V comprising the steps of: (a) heating sertraline hydrochloride Form XIII; and (b)
- the present invention also relates to sertraline hydrochloride Form XV which is
- the present invention also relates to a process for making sertraline hydrochloride
- Form XV comprising the steps of: (a) dissolving sertraline base in a solvent comprising a mixture of isopropanol and a non-polar solvent to form a solution of sertraline base; (b)
- the present invention also relates to a process for making sertraline hydrochloride
- Form XV comprising the steps of: (a) adding sertraline base to isopropanol; (b) adding
- the present invention also relates to a process for making sertraline hydrochloride
- Form V comprising the steps of: (a) heating sertraline hydrochloride Form XV; and (b)
- the present invention also relates to a process for preparing sertraline
- hydrochloride Form XVI comprising the steps of: (a) dissolving sertraline base in a
- solvent wherein the solvent is selected from the group consisting of hexane, cyclohexane
- XIV to a solvent selected from the group consisting of ethyl acetate, acetone, and t-butyl-
- the suspension is heated to a temperature range of
- the present invention also relates to processes for preparing sertraline
- hydrochloride Form II comprising the steps of: (a) adding sertraline hydrochloride Form
- the process further comprises the step of cooling the suspension
- hydrochloride Form II comprising the steps of: (a) adding sertraline hydrochloride Form XVI to a solvent selected from the group consisting of ethyl acetate and acetone to form a
- the present invention also relates to a method for treating obsessive-compulsive
- Sertraline hydrochloride Form XIV and Form XV are useful for preparing
- Figure 2 is a characteristic infrared absorption spectrum of sertraline
- Figure 4 is a characteristic powder X-ray diffraction pattern of sertraline
- the present invention provides; processes for preparing sertraline hydrochloride
- Form XI is a benzyl alcohol hemi-solvate of formula
- the invention further provides a method of obtaining sertraline hydrochloride Form XI
- alcohol may be toxic in large quantities, its administration in dosages contemplated by
- Benzyl alcohol is a
- Sertraline hydrochloride Form XI is characterized by its powder X-ray
- Sertraline hydrochloride Form XI is prepared by dissolving sertraline
- hydrochloride may be used, including, but not limited to sertraline hydrochloride Forms
- sertraline hydrochloride after it has completely dissolved in benzyl alcohol, is about 0.5
- solvates may also be obtainable by this method.
- Mono-solvates have a crystal structure
- preferred elevated temperature is 100°C when heating is used.
- sertraline hydrochloride Form XI may be induced by cooling from the elevated
- the resulting crystals may be isolated by any method known to the art, such as by
- Residual solvent can be removed by vacuum
- sertraline hydrochloride Form XI is heated under vacuum for a sufficient amount of time
- sertraline hydrochloride Form XI is heated to about 80°C, for about 24 h,
- Sertraline hydrochloride Form XI contains the
- hydrochloride Form XI is used alone, since the proportion is predetermined at 1 :2 by the
- hydrochloride Form XI and another form of sertraline hydrochloride, including, but not limited to sertraline hydrochloride sertraline hydrochloride Forms I-X, XII-XVI and
- sertraline hydrochloride and processes for making sertraline hydrochloride Form XII.
- sertraline hydrochloride Suitable forms of sertraline hydrochloride include, but are not
- Sertraline hydrochloride is the preferred starting
- the transformation may be monitored by x-ray powder diffraction techniques.
- hydrochloride Form XIN may be obtained by dissolving sertraline hydrochloride in
- the starting material sertraline hydrochloride is completely dissolved, any form
- sertraline hydrochloride may be used, including but not limited to, sertraline
- heating may be required to
- the solution may be allowed to cool, or be actively cooled, to a
- hydrochloride Form XIV may be separated from the solvent conventionally, as by
- sertraline hydrochloride Form II is made from sertraline hydrochloride Form II.
- sertraline hydrochloride Form XFV is made by adding sertraline hydrochloride
- Form II to methanol to form a suspension Preferably about 3 volumes of methanol are
- Form XIV is accelerated by heating the suspension to an elevated temperature.
- XIV is useful for preparing sertraline hydrochloride Form II. This process involves
- hydrochloride Form XIN in a solvent selected from the group consisting of ethyl acetate,
- Typical loadings range from about 5 volumes to about 20 volumes of solvent based upon
- the suspension is heated to reflux.
- the suspension is heated to reflux.
- Form II to be substantially complete.
- the suspension is heated for about 2 to
- Sertraline hydrochloride Form XIV is characterized by a powder X-ray diffraction pattern having reflections at about 7.4 ⁇ 0.2, 9.6 ⁇ 0.2, 12.0 ⁇ 0.2, 12.8 ⁇ 0.2, 14.3 ⁇ 0.2,
- hydrochloride designated sertraline hydrochloride Form XIII and processes for making
- sertraline hydrochloride Form XM sertraline hydrochloride Form XM.
- hydrochloride Form XIII may be obtained by heating sertraline hydrochloride Form XIN
- Form Xi ⁇ obtained in this manner is characterized by a powder X-ray diffraction pattern
- hydrochloride designated sertraline hydrochloride Form XV and processes for making
- sertraline hydrochloride Form XV sertraline hydrochloride Form XV.
- hydrochloride Form XV may be obtained by precipitation from aqueous solutions of
- a particularly preferred solvent is a mixture
- sertraline hydrochloride Form XV can be prepared without heating, though in solvent systems having a higher proportion of
- the temperature may further induce crystallization.
- the precipitated crystals may then be
- sertraline hydrochloride Form XV is another embodiment of the present invention.
- the isopropanol is warmed to about 40-50°C either before or after addition of
- hydrochloride Form XV may then be isolated by conventional methods. Sertraline base for use in the processes of the present invention may be produced
- No. 09/448,985 discloses sertraline hydrochloride Form VI and processes for making
- Sertraline hydrochloride Form VI may be made
- sertraline hydrochloride Form XV may be any suitable substance.
- Sertraline hydrochloride starting material based on the weight of the sertraline hydrochloride starting material.
- hydrochloride Form XV is preferably prepared by recrystallization from such a suspension
- Water may be provided by using aqueous
- the suspension is preferably heated to accelerate
- Sertraline hydrochloride Form XV may be isolated conventionally, e.g., by decanting or
- novel forms preferably to 70°C or above, more preferably 80°C or above, for sufficient
- the reaction may be monitored by powder x-ray
- sertraline hydrochloride Form XV is another embodiment of the present invention.
- Typical loadings range from about 5 volumes to about 20 volumes of solvent based upon
- the weight of sertraline hydrochloride Form XV more preferably about 10 volumes (herein volumes based on weight is measured in units of milliliters/gram or equivalently
- hydrochloride Form II is facilitated by heating the suspension to about 25°C to the reflux
- the suspension is heated to reflux.
- the suspension is heated to reflux.
- the suspension is heated for about 2 to about 3
- the suspension may be stirred at room temperature for a time
- the suspension is then cooled to a temperature range of about room temperature to
- sertraline hydrochloride Form II is isolated conventionally, e.g., by decanting or filtering.
- hydrochloride Form XVI is a form of sertraline hydrochloride with low-crystallinity
- Sertraline hydrochloride Form XVI may be prepared from
- nonpolar solvent system selected from the group consisting of hexane, cyclohexane and
- XVI, sertraline base is initially dissolved in hexane, cyclohexane or toluene. About 5 to
- the preferred elevated temperature is from about 30 °C to the reflux temperature of the
- solvent more preferably from about 40 °C to the reflux temperature of the solvent.
- gel formation may occur.
- Any gel that forms typically may be broken up so as to allow filtration or decanting, by
- XVI is useful for preparing sertraline hydrochloride Form II. This process involves
- loadings range from about 5 volumes to about 20 volumes of solvent based upon the
- Sertraline hydrochloride Form XVI is suspended for a time sufficient to induce the
- XI-XVI may be prepared as pharmaceutical compositions which are particularly useful for
- compositions of the present invention generally may
- compositions may also contain a pharmaceutically
- compositions may be in powder, granule, aggregate or any other solid state.
- these compositions may be prepared as medicaments to be
- forms for oral administration include tablets, compressed or coated pills, dragees, sachets,
- forms for parenteral administration include an aqueous or non-aqueous solution or
- emulsion while for rectal administration, suitable forms for administration include
- invention provides suitable transdermal delivery systems known in the art, and for nasal
- compositions for making tablets may have few or many components depending
- the release rate desired upon the tableting method used, the release rate desired and other factors. For example,
- compositions of the present invention may contain diluents such as cellulose-derived
- materials such as powdered cellulose, microcrystalline cellulose, microfine cellulose,
- methyl cellulose ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,
- unsubstituted celluloses starch; pregelatinized starch; inorganic diluents like calcium
- Suitable diluents include waxes, sugars and sugar alcohols such as
- mannitol and sorbitol acrylate polymers and copolymers, as well as pectin, dextrin and
- excipients include binders, such as acacia gum, pregelatinized starch, sodium
- novel forms of sertraline hydrochloride further include disintegrants such as sodium starch
- glycolate crospovidone, low-substituted hydroxypropyl cellulose and others.
- Additional excipients include tableting lubricants such as magnesium and calcium stearate, sodium
- stearyl fumarate and polyethylene glycol stearyl fumarate and polyethylene glycol; flavorings; sweeteners; preservatives;
- Capsule dosages will contain the composition within a capsule which
- Tablets and powders may be made of gelatin or other encapsulating material. Tablets and powders may be
- the coating may be an enteric coating or non-enteric coating. Suitable coatings
- enteric-coated powder forms include phthalic acid cellulose acetate,
- carboxymethylethylcellulose a copolymer of styrene and maleic acid, a copolymer of
- methacrylic acid and methyl methacrylate, and like materials may be
- a coated tablet may have a
- the prefe ⁇ ed dosage of the present invention is an oral tablet.
- Other oral dosage is an oral tablet.
- forms including pills, capsules, dragees, cachets, troches, pellets, suspensions, powders,
- lozenges, elixirs and the like may also be used, as well as suppositories, ointments,
- present invention may be dissolved in solutions to deliver sertraline hydrochloride and a
- Preferred solid oral dosages of the present invention contain from about 25 mg to
- More preferable oral dosages contain about 50-120 mg of one or more of the
- Sertraline hydrochloride Form XI was heated to 80 °C under vacuum for 24 h. The
- Sertraline hydrochloride Form V (100 mg) was placed in a 10 mL glass bottle.
- the uncapped bottle was set in a pool of water at the bottom of a larger bottle.
- the dried crystals were identified as sertraline hydrochloride Form XM by their powder
- Sertraline hydrochloride Form II (7 g) was suspended in methanol (21 mL) and
- Sertraline hydrochloride Form XIV crystals were dried at 80 °C for 24 h to give
- sertraline hydrochloride identified as a novel form of sertraline hydrochloride (designated sertraline hydrochloride
- Sertraline hydrochloride Form XV was isolated by conventional methods, including, but
- Sertraline hydrochloride Form VI (40 g) was suspended in isopropanol (120 mL)
- Sertraline base (5 g) was suspended in cyclohexane (50 L) and the suspension
- Form XVI sertraline hydrochloride
- the powder X-ray spectrum of Form XVI has two broad reflections at 15.6 and 23.0 at 2 ⁇ .
- Sertraline base (5 g) was suspended in hexane (50 mL) and the suspension was
- Sertraline hydrochloride Form XVI (5 g) was suspended in acetone (50 mL) and
- Sertraline hydrochloride Form XIV (3 g) was suspended in ethyl acetate (45 mL).
- Sertraline hydrochloride Form XIV (3 g) was suspended in acetone (30 ml). The
- hydrochloride Form II was isolated by filtration.
- Sertraline hydrochloride Form XV (6 g) was suspended in acetone (60 ml). The
- Sertraline hydrochloride Form XV (6 g) was suspended in cyclohexane (60 ml).
- the suspension was heated at 60°C for 3 hours to facililtate the transformation of sertraline hydrochloride Form XV to sertraline hydrochloride Form II.
- the suspension was heated at 60°C for 3 hours to facililtate the transformation of sertraline hydrochloride Form XV to sertraline hydrochloride Form II.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0204010A HUP0204010A3 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use |
SK887-2002A SK8872002A3 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
EP00990336A EP1248605B1 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
JP2001546631A JP4057295B2 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, methods for preparing them, compositions containing them and methods using them |
EP07001701A EP1797875A3 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
IL15033200A IL150332A0 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
AU27376/01A AU780771B2 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
DK00990336T DK1248605T3 (en) | 1999-12-21 | 2000-12-21 | Newly known sertraline hydrochloride polymorphs, processes for their preparation, compositions containing them and methods for their use |
DE60033566T DE60033566T2 (en) | 1999-12-21 | 2000-12-21 | NEW SERTRALINE HYDROCHLORIDE POLYMORPHES, METHOD FOR THE PRODUCTION AND USE THEREOF AND COMPOSITIONS CONTAINING THEREOF |
IS6425A IS6425A (en) | 1999-12-21 | 2002-06-18 | New sertraline hydrochloride polyphenols, methods for making them, mixtures containing them and methods for using them |
HR20020543A HRP20020543A2 (en) | 1999-12-21 | 2002-06-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17134199P | 1999-12-21 | 1999-12-21 | |
US60/171,341 | 1999-12-21 | ||
US18733600P | 2000-03-06 | 2000-03-06 | |
US60/187,336 | 2000-03-06 | ||
US18791000P | 2000-03-08 | 2000-03-08 | |
US60/187,910 | 2000-03-08 | ||
US19060300P | 2000-03-20 | 2000-03-20 | |
US60/190,603 | 2000-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001045692A1 WO2001045692A1 (en) | 2001-06-28 |
WO2001045692A9 true WO2001045692A9 (en) | 2002-07-04 |
Family
ID=27496950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/035178 WO2001045692A1 (en) | 1999-12-21 | 2000-12-21 | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them |
Country Status (19)
Country | Link |
---|---|
US (2) | US6452054B2 (en) |
EP (2) | EP1797875A3 (en) |
JP (2) | JP4057295B2 (en) |
KR (1) | KR100791872B1 (en) |
CN (1) | CN1434708A (en) |
AT (1) | ATE354358T1 (en) |
AU (1) | AU780771B2 (en) |
DE (1) | DE60033566T2 (en) |
DK (1) | DK1248605T3 (en) |
ES (1) | ES2281374T3 (en) |
HR (1) | HRP20020543A2 (en) |
HU (1) | HUP0204010A3 (en) |
IL (1) | IL150332A0 (en) |
IS (1) | IS6425A (en) |
PL (1) | PL356452A1 (en) |
PT (1) | PT1248605E (en) |
SK (1) | SK8872002A3 (en) |
WO (1) | WO2001045692A1 (en) |
YU (1) | YU47902A (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6978342B1 (en) | 1995-07-31 | 2005-12-20 | Lexar Media, Inc. | Moving sectors within a block of information in a flash memory mass storage architecture |
US5845313A (en) | 1995-07-31 | 1998-12-01 | Lexar | Direct logical block addressing flash memory mass storage architecture |
US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
US6495721B1 (en) * | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
TWI260315B (en) | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
DE60033566T2 (en) | 1999-12-21 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | NEW SERTRALINE HYDROCHLORIDE POLYMORPHES, METHOD FOR THE PRODUCTION AND USE THEREOF AND COMPOSITIONS CONTAINING THEREOF |
JP2003527359A (en) * | 2000-03-14 | 2003-09-16 | テバ ファーマシューティカル インダストリーズ リミティド | New method for the production of (+)-cis-sertraline |
US7067700B2 (en) | 2001-05-31 | 2006-06-27 | Fermion Oy | Process for preparing sertraline hydrochloride polymorphic form II |
WO2002096860A1 (en) * | 2001-05-31 | 2002-12-05 | Orion Corporation Fermion | Process for preparing sertraline intermediates |
GB0123421D0 (en) | 2001-09-28 | 2001-11-21 | Memquest Ltd | Power management system |
AU2003251290A1 (en) * | 2002-04-29 | 2003-11-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof |
US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
US20040131672A1 (en) * | 2003-01-07 | 2004-07-08 | Nilobon Podhipleux | Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties |
US7186863B2 (en) | 2003-05-23 | 2007-03-06 | Transform Pharmaceuticals, Inc. | Sertraline compositions |
CA2537804A1 (en) * | 2003-09-05 | 2005-03-17 | Teva Pharmaceutical Industries Ltd | A recycling process for preparing sertraline |
DE602004027401D1 (en) * | 2003-11-04 | 2010-07-08 | Cipla Ltd | PROCESS FOR PREPARING POLYMORPHES OF SERTRALINE HYDROCHLORIDE |
US7464306B1 (en) | 2004-08-27 | 2008-12-09 | Lexar Media, Inc. | Status of overall health of nonvolatile memory |
US7345201B2 (en) * | 2005-02-23 | 2008-03-18 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing sertraline |
WO2006103506A1 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Sertraline-containing pharmaceutical compositions and a process for preparation thereof |
GB0507090D0 (en) * | 2005-04-07 | 2005-05-11 | Sandoz Ag | Process for preparing polymorphic form ll of sertraline hydrochloride |
US7518019B2 (en) | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
US20060257475A1 (en) * | 2006-08-17 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Stable Sertraline Hydrochloride Formulation and Method |
CA2594198A1 (en) * | 2007-07-20 | 2009-01-20 | Apotex Pharmachem Inc. | A novel process for the preparation of sertraline hydrochloride form ii |
FR2928148B1 (en) * | 2008-02-28 | 2013-01-18 | Sanofi Aventis | PROCESS FOR PREPARING COMBRETASTATIN |
JP2016537365A (en) | 2013-11-15 | 2016-12-01 | アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. | {[5- (3-Chlorophenyl) -3-hydroxypyridine-2-carbonyl] amino} acetic acid solid form, composition and use thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US5082970A (en) | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
GB9114947D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline |
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
US5734083A (en) * | 1996-05-17 | 1998-03-31 | Torcan Chemical Ltd. | Sertraline polymorph |
PT1064250E (en) | 1998-03-18 | 2004-09-30 | Ciba Sc Holding Ag | PROCESS FOR HYDROGENATION CATALYTIC CIS-SELECTIVE CYCLE-HEXYLIDENAMINS |
JP2000026379A (en) * | 1998-07-08 | 2000-01-25 | Sumika Fine Chemicals Co Ltd | Sertraline hydrochloride methanolated substance and sertraline hydrochloride ethanolated substance and their production |
IL143311A0 (en) * | 1998-11-27 | 2002-04-21 | Teva Pharma | Sertraline hydrochloride polymorphs |
US6500987B1 (en) * | 1998-11-27 | 2002-12-31 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride polymorphs |
US6495721B1 (en) | 1999-08-09 | 2002-12-17 | Teva Pharmaceutical Industries Ltd. | Sertraline hydrochloride Form II and methods for the preparation thereof |
TWI260315B (en) * | 1999-10-29 | 2006-08-21 | Ciba Sc Holding Ag | Polymorphic forms of sertraline hydrochloride |
DE60033566T2 (en) * | 1999-12-21 | 2007-10-25 | Teva Pharmaceutical Industries Ltd. | NEW SERTRALINE HYDROCHLORIDE POLYMORPHES, METHOD FOR THE PRODUCTION AND USE THEREOF AND COMPOSITIONS CONTAINING THEREOF |
IN192343B (en) | 2000-05-26 | 2004-04-10 | Ranbaxy Lab Ltd |
-
2000
- 2000-12-21 DE DE60033566T patent/DE60033566T2/en not_active Expired - Fee Related
- 2000-12-21 SK SK887-2002A patent/SK8872002A3/en unknown
- 2000-12-21 EP EP07001701A patent/EP1797875A3/en not_active Withdrawn
- 2000-12-21 DK DK00990336T patent/DK1248605T3/en active
- 2000-12-21 JP JP2001546631A patent/JP4057295B2/en not_active Expired - Fee Related
- 2000-12-21 PL PL00356452A patent/PL356452A1/en unknown
- 2000-12-21 CN CN00819123A patent/CN1434708A/en active Pending
- 2000-12-21 US US09/746,320 patent/US6452054B2/en not_active Expired - Lifetime
- 2000-12-21 KR KR1020027007897A patent/KR100791872B1/en not_active IP Right Cessation
- 2000-12-21 WO PCT/US2000/035178 patent/WO2001045692A1/en active IP Right Grant
- 2000-12-21 ES ES00990336T patent/ES2281374T3/en not_active Expired - Lifetime
- 2000-12-21 EP EP00990336A patent/EP1248605B1/en not_active Expired - Lifetime
- 2000-12-21 IL IL15033200A patent/IL150332A0/en unknown
- 2000-12-21 AT AT00990336T patent/ATE354358T1/en not_active IP Right Cessation
- 2000-12-21 YU YU47902A patent/YU47902A/en unknown
- 2000-12-21 PT PT00990336T patent/PT1248605E/en unknown
- 2000-12-21 AU AU27376/01A patent/AU780771B2/en not_active Ceased
- 2000-12-21 HU HU0204010A patent/HUP0204010A3/en unknown
-
2002
- 2002-06-18 IS IS6425A patent/IS6425A/en unknown
- 2002-06-21 HR HR20020543A patent/HRP20020543A2/en not_active Application Discontinuation
- 2002-09-13 US US10/243,293 patent/US6858652B2/en not_active Expired - Lifetime
-
2007
- 2007-06-20 JP JP2007163172A patent/JP2007308505A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2001045692A1 (en) | 2001-06-28 |
ES2281374T3 (en) | 2007-10-01 |
EP1248605A2 (en) | 2002-10-16 |
DK1248605T3 (en) | 2007-03-19 |
DE60033566T2 (en) | 2007-10-25 |
JP2003518056A (en) | 2003-06-03 |
US20010041815A1 (en) | 2001-11-15 |
SK8872002A3 (en) | 2002-12-03 |
US20030023117A1 (en) | 2003-01-30 |
HUP0204010A2 (en) | 2003-04-28 |
YU47902A (en) | 2005-11-28 |
HRP20020543A2 (en) | 2005-04-30 |
DE60033566D1 (en) | 2007-04-05 |
EP1797875A3 (en) | 2007-08-29 |
PL356452A1 (en) | 2004-06-28 |
US6858652B2 (en) | 2005-02-22 |
AU2737601A (en) | 2001-07-03 |
KR20020062356A (en) | 2002-07-25 |
JP2007308505A (en) | 2007-11-29 |
JP4057295B2 (en) | 2008-03-05 |
AU780771B2 (en) | 2005-04-14 |
EP1248605A4 (en) | 2004-11-24 |
PT1248605E (en) | 2007-03-30 |
IL150332A0 (en) | 2002-12-01 |
ATE354358T1 (en) | 2007-03-15 |
US6452054B2 (en) | 2002-09-17 |
CN1434708A (en) | 2003-08-06 |
EP1797875A2 (en) | 2007-06-20 |
IS6425A (en) | 2002-06-18 |
KR100791872B1 (en) | 2008-01-07 |
HUP0204010A3 (en) | 2006-02-28 |
EP1248605B1 (en) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6452054B2 (en) | Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them | |
US20180029987A1 (en) | Crystalline forms of pitavastatin calcium | |
US7319171B2 (en) | Sertraline hydrochloride form II and methods for the preparation thereof | |
US20070238738A1 (en) | Crystalline ziprasidone HCI and processes for preparation thereof | |
WO2003051818A1 (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form | |
EP1772144A2 (en) | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them | |
ZA200204971B (en) | Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them. | |
ZA200404332B (en) | A novel polymorph of sertraline hydrochloride and composition containing thereof, novel methods for preparation of sertraline hydrochloride polymorphs and amorphous form. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-479/02 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-2117 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 27376/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8872002 Country of ref document: SK Ref document number: IN/PCT/2002/00832/MU Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2001 546631 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/04971 Country of ref document: ZA Ref document number: 150332 Country of ref document: IL Ref document number: 1020027007897 Country of ref document: KR Ref document number: 200204971 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20020543A Country of ref document: HR |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000990336 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2002 2002116782 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027007897 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 008191239 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2000990336 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-2117 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 27376/01 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000990336 Country of ref document: EP |